Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 20, 2015

View Archived Issues

Cempra reports topline phase III data for intravenous solithromycin

Novel polymyxin derivatives show antibacterial activity

Sunshine Lake Pharma reports anti-HBV agents

Radiolabeled G-02113 may be useful for in vivo imaging of sst receptor-expressing tumors

PharmaCyte outlines plans for upcoming pancreatic cancer trial of Cell-in-a-Box + ifosfamide

Medifocus in license agreement with Duke for heat-activated and tumor-targeted immunotherapy

Alnylam describes a more potent RNAi agent targeting transthyretin for treating amyloidosis

Profiling of novel inhibitors of bacterial topoisomerases

Avalanche Biotechnologies reports 1-year follow up from phase I trial of rAAV.sFLT-1

Agios Pharmaceuticals provides pipeline update

Kowa files for approval of pemafibrate in Japan

Genocea reports topline results from phase IIa trial of universal Pneumococcal vaccine

Addyi launched in the U.S. for generalized hypoactive sexual desire disorder

Allergan completes acquisition of AqueSys

Novel JAK3 inhibitor shows promise for Th2-driven diseases

European Commission approves isavuconazole for invasive aspergillosis and mucormycosis

Roche discloses CB2 inverse agonists

Syros Pharmaceuticals patents CDK7 inhibitors

Instytut Farmaceutyczny reports antineoplastic agents

Calitor Sciences presents protein kinase inhibitors

Orion presents TRPA1 antagonists

Inotuzumab ozogamicin receives FDA breakthrough therapy designation for ALL

CFTR amplifiers enhance the effect of CFTR modulators

La Jolla Pharmaceutical starts phase I trial of hepcidin formulation LJPC-401

Avedro resubmits NDA for corneal cross-linking system

GenKyoTex's GKT-137831 granted U.S. orphan status for systemic sclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...